Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eravacycline - Tetraphase Pharmaceuticals

Next Previous
Search
Drug Profile

Eravacycline - Tetraphase Pharmaceuticals

Alternative Names: TP-434; XERAVA

Latest Information Update: 17 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Paratek Pharmaceuticals
  • Developer Everest Medicines; PAION; Tetraphase Pharmaceuticals
  • Class Acetamides; Anti-infectives; Antibacterials; Antivirals; Fluorinated hydrocarbons; Pyrrolidines; Small molecules; Tetracyclines; Urinary anti-infective agents
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Intra-abdominal infections
  • No development reported Bacterial infections; Respiratory tract infections
  • Discontinued Urinary tract infections

Most Recent Events

  • 04 Apr 2025 Phase-II clinical trials in Intra-abdominal infections (Complicated, In children, In adolescents) in USA (IV) (NCT06794541)
  • 27 Sep 2023 Registered for Intra-abdominal infections in Taiwan (IV)
  • 21 Sep 2023 Paratek Pharmaceuticals has been acquired by Gurnet Point Capital and Novo Holdings

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top